L 689502

HIV-1 protease inhibitor; structure given in first source

Also Known As:

L-689,502; Carbamic acid, (5-((2,3-dihydro-2-hydroxy-1H-inden-1-yl)amino)-2-hydroxy-4-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-5-oxo-1-(phenylmethyl)pentyl)-, 1,1-dimethylethyl ester, (1S-(1alpha(1R*,2R*,4S*),2alpha))-

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - Morpholines: 6
      - L 689502: 1
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - L 689502: 1

Related Diseases

1.	Necrosis 09/01/1997 - "Histological examination of perfusion-fixed livers 30 min after L-689,502 administration revealed periportal changes including hepatocyte vacuolation and occasional single cell necrosis. "
2.	Cholestasis 09/01/1997 - "Oral administration of the HIV protease inhibitor L-689,502 caused cholestasis and hepatocyte injury in rats and dogs. "

Related Drugs and Biologics

1.	HIV Protease Inhibitors

Related Therapies and Procedures

1.	Oral Administration